Lancet Oncology

Article	Citations
Navigating the complexity: reflections on the development of perioperative cancer treatments	655
Dual therapy in metastatic castration-resistant prostate cancer	596
US FDA proposes stronger laboratory test oversight	533
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	479
Palliative radiotherapy for hepatic cancer pain	464
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply	462
SANO trial: innovations, risks, and unanswered questions	405
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	399
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	398
Toxicity assessment bias in the PACE-C trial – Authors' reply	393
New national cancer registry for France	379
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX	348
The future of precise cancer chronotherapeutics	343
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply	319
Olanzapine for chemotherapy-induced nausea and vomiting control	300
Study bolsters concerns about US FDA accelerated drug approvals	290
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	288
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	285
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	283
Combination immunotherapy in chemotherapy in gastric cancer	271
Patients with cancer in Louisiana denied fertility preservation cover	260
Use of artificial intelligence to enhance detection of nodal metastases	260
The GLOW trial in chronic lymphocytic leukaemia	254
Precision medicine for children with cancer	251
Concern for cancer drugs in USA–EU tariff war	249

IVLBCL mimicking VEXAS syndrome	249
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation	249
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	246
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	243
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial	233
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment	221
US Surgeon General calls for cancer warning labels on alcohol	219
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	218
Correction to Lancet Oncol 2022; 23: 1124–26	218
The silent malignant mesothelioma epidemic: a call to action	216
Determining the optimal use of approved drugs in oncology	207
ALND after neoadjuvant chemotherapy: a call for caution	204
Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer	199
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	197
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	196
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	189
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas	188
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o	187
A new generation of comprehensive precision oncology trials	180
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	178
Clinical benefit and the Trump administration's cancer medicine reforms	178
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	176
Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers	169
Italy to pass law on the right to be forgotten for cancer survivors	169
Correction to Lancet Oncol 2021; 22: 1081–92	166
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	166
Health insurance system in Japan faces risk of politicisation	165
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus	165
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospec	164
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	164
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	155
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	149
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	145
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	145
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	144
Innovation in gynaecological cancer: highlighting global disparities	144
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	139
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	138
Mantle cell lymphoma: is it time for risk-adapted treatment?	138
Cancer on the agenda during IAEA Director General's visit to Chile	137
Lung cancer rates highest among British Bangladeshi men	136
Balancing clinical benefit and social value: challenges in HTA assessments	135
Daratumumab maintenance in patients with myeloma	133
Challenges and prospects for cancer treatment in prison settings	132
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:	131
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	127
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	124
Clearing the radiotherapy backlog: innovation to pave the way	123
Common Sense Oncology: including everyone	120
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	119

Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	118
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study	116
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	116
Importance of clinical research for the UK's 10-year cancer plan	116
Essential anticancer medicines for children: defining what matters most for Europe	115
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	114
Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer	114
The power of words: evaluating the role of qualitative methods in cancer research	112
Decentralised, point-of-care CAR-T for multiple myeloma	111
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	111
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	106
Oral contraceptives and risk of liver cancer	106
WHO reports health service disruptions due to suspensions of aid	105
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	104
Systemic therapy for brain metastases: a changing landscape	104
ESMO Congress 2025	103
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer	103
Antimicrobial resistance in patients with haematological malignancies: a scoping review	102
India rolls out HPV vaccination	102
Canada's Yukon Territory publishes First Nations Cancer Strategy	99
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	99
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	99
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials	98
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	97
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	96
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	96
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	96
Radiotherapy and conflict: from disruption to expansion and hope	95
Focus where it matters: turning insights into advocacy	93
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study	92
Daratumumab–lenalidomide and the immunosuppressive budget in myeloma – Authors' reply	90
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	89
Correction to Lancet Oncol 2020; 21: 699–709	89
2022 ASTRO annual meeting	88
Syrian cancer patients regain treatment access in Türkiye	87
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	87
Correction to Lancet Oncol 2023; 24: e242	87
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	87
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	86
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer	85
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	85
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial	85
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	85
Findings suggest under-reporting of patient data in US SEER	84
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	84
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	84
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	83
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	82
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	82
Endometrial cancer: the individual approach	81
Medical debt of people with cancer in the USA	80
Progress in global tobacco control measures	80
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	79
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	79
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group	79
Promoting cancer prevention through World Cancer Day in Nigeria	78
South Africa's new tobacco and e-cigarette control bill	77
A red patch on the palate	77
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	77
Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis	77
AACR Annual Meeting 2023	77
Transforming cancer: behind the scenes at the Crick Institute	76
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	76
Internationally trained doctors in the USA	76
The importance of preventing occupational cancer	75
On a precipice: the UK's broken health-care system	74
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	73
Correction to Lancet Oncol 2023; 24: 1181–95	73
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	72
Correction to Lancet Oncol 2024; 25: e126–35	72
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	71
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	71
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	71
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	70
Managing immune checkpoint inhibition in transplant recipients	70
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	69
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	68
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	68
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	68
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	67

Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice	67
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	65
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	65
Challenging cancer through poetry	65
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	65
Stereotactic ablative radiotherapy for primary kidney cancer	65
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	65
American Lung Association calls for expanded insurance coverage for lung cancer screening	63
Anticipating the future of cancer care in Trump's America	63
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	62
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	62
Rwanda provides free treatment to all cancer patients	62
US lawmakers call on Biden Administration to lower the price of enzalutamide	62
Abemaciclib for malignant pleural mesothelioma – Authors' reply	61
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	61
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply	61
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	61
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	61
Quality control and childhood cancer medicines	60
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study	59
Sharp increase in patients waiting months for urgent cancer treatment	59
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	59
Management of locally advanced gastric cancer	58
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	58
US Clean Air in the firing line	58
WHO calls for investment in cancer prevention and care within a wider NCD strategy	58
Sharing a personal story behind brain cancer	58
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	57
US cancer research might never recover from proposed Trump funding cuts	57
Sharing experiences and forming bonds at the Edinburgh Fringe	56
Delay to England's National Cancer Plan could cost lives	56
Between the lines: an oncology diary no one assigned	56
Correction to Lancet Oncol 2025; 26: 548–49	55
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	55
Correction to Lancet Oncol 2023; 24: 91–106	55
Correction to Lancet Oncol 2023; 24: e472–518	55
Correction to Lancet Oncol 2022; 23: 1297–307	55
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	54
New evidence for brain cancer risk after a single paediatric CT scan	54
HPV vaccine roll-out in Nigeria and Bangladesh	54
Immunotherapy: balancing the risks and benefits	54
US legislation might soon allow easier access to cancer medications	53
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases	53
PSMA-PET research: addressing challenges and prospects – Authors' reply	53
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	53
San Antonio Breast Cancer Symposium 2025	52
Correction to Lancet Oncol 2026; 27: 233–42	52
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma	52
Problems with catch-up HPV vaccination after resumption of proactive recommendations	52
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	51
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	51
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	51
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	50
The changing global landscape of national cancer control plans	50
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-02	50
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	50
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	49
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label,	49
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase	49
AKT-targeted triplet therapy in advanced breast cancer	49
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study	49
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-	48
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label	48
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	48
Qatar national cancer care and research: pioneering strategies for global health excellence	48
PMI faces questions over cigarette marketing and smoke-free commitments	48
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	47
Improved cancer coverage for firefighters in Western Australia	46
US drinking water polluted with carcinogenic nitrates	46
Indonesia and the Philippines take steps to control cancer	46
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	46
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	46
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed	46
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement	45
Cancer risk estimates for US EPA-approved alternative plastic-based fuel cause alarm	44
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	44
BrECADD and fertility: an ongoing concern	44
BrECADD and fertility: an ongoing concern – Authors' reply	43
US mRNA cancer vaccine research faces an uncertain future	43
Correction to Lancet Oncol 2024; 25: 1625–34	42
Correction to Lancet Oncol 2022; 23: 416–27	42
Correction to Lancet Oncol 2024; 25: 317–25	42
Reflections on the PEACE V–STORM trial	42
Solutions for tackling the global surgery crisis in west Africa	41
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?	41
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma	41
Curbing the climb in cancer incidence	41
Cryptic metastatic calcification after radical nephrectomy in a patient with renal cell carcinoma	41
Correction to Lancet Oncol 2024; 25: 744–59	41
HPV vaccination in south Asia: new progress, old challenges	41
US National Firefighter Registry for Cancer shuts down amid layoffs	41
Losing my brother, finding myself	40
Cyber-attacks on health-care systems	40
Treatment of Richter transformation—immunotherapy to the rescue?	40
Utilising cancer registry data to monitor cancer burden	40